Certara to Participate in the Stephens Annual Investment Conference
- RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.
- 10/28/2024
|
Certara Appoints John Reynders as New Independent Board Member
- RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
- 10/16/2024
|
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
- RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the third quarter of 2024 after the market close on Wednesday, November 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 10/09/2024
|
Certara Completes Acquisition of Chemaxon
- Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry.
- 10/02/2024
|
Final Trade: Certara, Nextera Energy, Knight-Swift Transportation and Lululemon
- The final trades of the day with the Fast Money traders.
- 09/27/2024
|
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
- Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001.
- 09/18/2024
|
Certara to Participate in Upcoming Investor Conferences
- RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
- 08/21/2024
|
Certara Launches Phoenix™ Version 8.5 Drug Development Software
- RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5.
- 08/15/2024
|
Certara, Inc. (CERT) Q2 2024 Earnings Call Transcript
- Certara, Inc. (NASDAQ:CERT ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations, Gilmartin Group LLC William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens David Windley - Jefferies Dan Clark - Leerink Partners Joe Vruwink - Baird Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara Second Quarter 2024 Earnings Conference Call.
- 08/06/2024
|
Certara, Inc. (CERT) Q2 Earnings and Revenues Lag Estimates
- Certara, Inc. (CERT) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.12 per share a year ago.
- 08/06/2024
|
Certara Reports Second Quarter 2024 Financial Results
- RADNOR, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2024.
- 08/06/2024
|
Certara to Acquire Chemaxon to Strengthen Drug Discovery Software Portfolio
- Combined organization brings broader predictive capabilities to drug discovery at scale Reiterates full year 2024 guidance RADNOR, Pa., July 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has signed a definitive agreement to acquire Chemaxon, a leading provider of cheminformatics software.
- 07/09/2024
|
Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024
- RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 07/02/2024
|
Certara Launches Next Generation CoAuthor™ Generative AI Regulatory Writing Software
- Certara today unveiled its next-generation CoAuthor regulatory writing software. CoAuthor is an advanced writing platform designed for medical writers.
- 06/17/2024
|
Certara to Participate in the Jefferies Global Healthcare Conference
- RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
- 05/29/2024
|
Certara Appoints New Chief Human Resources Officer & General Counsel
- RADNOR, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.
- 05/21/2024
|
Swiss National Bank Reduces Stock Holdings in Certara, Inc. (NASDAQ:CERT)
- Swiss National Bank cut its position in shares of Certara, Inc. (NASDAQ:CERT – Free Report) by 16.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 220,400 shares of the company’s stock after selling 43,200 shares during the period. Swiss National Bank owned approximately 0.14% of Certara worth $3,877,000 at the end of the most recent quarter. Several other institutional investors and hedge funds also recently bought and sold shares of the company. Commonwealth Equity Services LLC lifted its holdings in Certara by 31.2% in the third quarter. Commonwealth Equity Services LLC now owns 19,055 shares of the company’s stock valued at $277,000 after acquiring an additional 4,528 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Certara by 16.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,117 shares of the company’s stock valued at $351,000 after purchasing an additional 3,482 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Certara by 19.2% in the 3rd quarter. M&T Bank Corp now owns 141,368 shares of the company’s stock valued at $2,055,000 after purchasing an additional 22,759 shares during the last quarter. EFG Asset Management North America Corp. purchased a new position in shares of Certara during the 3rd quarter worth $1,570,000. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Certara during the 3rd quarter worth about $941,000. 73.96% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling at Certara In other news, SVP Richard M. Traynor sold 3,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the transaction, the senior vice president now owns 173,524 shares in the company, valued at approximately $3,123,432. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, SVP Richard M. Traynor sold 3,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $18.00, for a total value of $54,000.00. Following the completion of the sale, the senior vice president now directly owns 173,524 shares of the company’s stock, valued at $3,123,432. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 14,427 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $16.85, for a total value of $243,094.95. Following the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $844,033.35. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by insiders. Certara Price Performance Shares of CERT opened at $16.08 on Monday. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -41.23, a PEG ratio of 1.61 and a beta of 1.61. The firm’s fifty day simple moving average is $17.41 and its 200-day simple moving average is $16.66. Certara, Inc. has a twelve month low of $11.81 and a twelve month high of $22.65. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.04). Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. The business had revenue of $88.01 million for the quarter, compared to analysts’ expectations of $86.80 million. Equities analysts forecast that Certara, Inc. will post 0.29 EPS for the current fiscal year. Analyst Ratings Changes Several research analysts have weighed in on the stock. Barclays increased their target price on shares of Certara from $16.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. UBS Group lifted their target price on shares of Certara from $17.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, March 1st. Leerink Partnrs restated a “market perform” rating on shares of Certara in a research note on Monday, February 26th. Jefferies Financial Group lifted their price objective on Certara from $14.00 to $15.50 and gave the company a “hold” rating in a research note on Friday, March 1st. Finally, SVB Leerink started coverage on Certara in a research note on Monday, February 26th. They set a “market perform” rating and a $19.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average price target of $20.06. View Our Latest Research Report on CERT Certara Company Profile (Free Report) Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
- 05/20/2024
|
Certara, Inc. (CERT) Q1 2024 Earnings Call Transcript
- Certara, Inc. (NASDAQ:CERT ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Luke Sergott - Barclays Michael Ryskin - Bank of America Max Smock - William Blair Steve Dechert - KeyBanc Operator Good day and thank you for standing by. Welcome to the Certara First Quarter 2024 Earnings Conference Call.
- 05/08/2024
|
Certara, Inc. (CERT) Q1 Earnings Meet Estimates
- Certara, Inc. (CERT) came out with quarterly earnings of $0.10 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.12 per share a year ago.
- 05/07/2024
|
Certara Reports First Quarter 2024 Financial Results
- PRINCETON, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2024.
- 05/07/2024
|
Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform
- Certara Cloud is a unifying platform that integrates Certara's scientific software. Clients use a single ID to access and manage their licensed software.
- 04/16/2024
|
Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference
- PRINCETON, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2024 after the market close on Tuesday, May 7th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 04/09/2024
|
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
- Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
- 02/29/2024
|
Certara, Inc. (CERT) Lags Q4 Earnings Estimates
- Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
- 02/29/2024
|
Certara Reports Fourth Quarter 2023 Financial Results
- PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter of fiscal year 2023.
- 02/29/2024
|
Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference
- PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2023 after the market close on Thursday, February 29th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 02/01/2024
|
Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
- Certara: Applied BioMath Acquisition And Simcyp Launch Should Drive Growth
- 01/30/2024
|
Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies
- PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced it has acquired Applied BioMath, an industry-leader in providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development (R&D).
- 12/13/2023
|
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
- Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
- 11/21/2023
|
Certara Inc. (CERT) Q3 2023 Earnings Call Transcript
- Certara Inc. (NASDAQ:CERT ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc David Windley - Jefferies Mike Ryskin - Bank of America Max Smock - William Blair Joe Vruwink - Baird Vikram Purohit - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call.
- 11/08/2023
|
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
- Certara, Inc. (CERT) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.10 per share a year ago.
- 11/08/2023
|
Certara Reports Third Quarter 2023 Financial Results
- PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023.
- 11/08/2023
|
Circling Back On Certara
- Certara, Inc. provides biosimulation software and services to the biotech and biopharma industry. The company is enjoying sales growth from its software division in the mid-teen but service growth is lagging. Analysts have mixed opinions on Certara's prospects even as the company is expanding its AI capabilities. An updated analysis is provided in the paragraphs below.
- 10/17/2023
|
Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference
- PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023 after the market close on Wednesday November 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 10/11/2023
|
Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
- Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines Dedicated team of global regulatory experts delivers submissions in increasingly shorter timelines
- 09/19/2023
|
Certara to Participate in Upcoming Investor Conferences
- PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:
- 08/29/2023
|
Certara Simcyp™ Group Awarded Two New Grants from US FDA
- Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations Programs focus on use of physiologically-based pharmacokinetic (PBPK) modeling for demonstrating virtual bioequivalence and predicting drug absorption of topical formulations
- 08/29/2023
|
Certara stock drops after biotech software company misses profit target
- Certara Inc. CERT, -2.56% stock was down 14.6% in premarket trades on Thursday after the biotech software company missed Wall Street's adjusted earnings and revenue targets and said its 2023 profit would fall short of analyst forecasts. The company's second-quarter adjusted profit of 12 cents a share missed the FactSet consensus estimate of 13 cents a share, while its revenue of $90.5 million fell short of the analyst target of $92.2 million.
- 08/10/2023
|
Certara Inc. (CERT) Q2 2023 Earnings Call Transcript
- Certara Inc. (NASDAQ:CERT ) Q2 2023 Results Conference Call August 9, 2023 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO and Director John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Vikram Purohit - Morgan Stanley Jeff Garro - Stephens Inc Kyle Crews - Credit Suisse Financial Services Max Smock - William Blair Gaurav Goparaju - Berenberg Capital Markets Joe Vruwink - Baird Operator Good day, and thank you for standing by. Welcome to the Certara Second Quarter 2023 Earnings Call.
- 08/09/2023
|
Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023
- PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2023 after the market close on Wednesday, August 9th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 07/13/2023
|
Certara to Participate in the Jefferies Global Healthcare Conference
- PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
- 06/02/2023
|
Certara, Inc. (CERT) Q1 2023 Earnings Call Transcript
- Certara, Inc. (NASDAQ:CERT ) Q1 2023 Results Conference Call May 8, 2023 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO John Gallagher - CFO Conference Call Participants David Windley - Jefferies Vikram Purohit - Morgan Stanley Jeff Garro - Stephens Inc. Luke Sergott - Barclays Max Smock - William Blair Wolf Chanoff - Bank of America Joy Zhang - SVB Securities Gaurav Goparaju - Berenberg Capital Markets Joe Vruwink - Baird Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2023 Earnings Conference Call.
- 05/08/2023
|
5 Must-Buy High-Flying Mid-Cap Stocks Ahead of Q1 Earnings
- We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.
- 04/28/2023
|
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
- PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2023 after the market close on Monday, May 8th, 2023. Company management will host a conference call to discuss financial results at 5:00PM ET.
- 04/10/2023
|
MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study
- As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.
- 04/06/2023
|
GSK's Jemperli Effective Against First-Line Endometrial Cancer
- A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
- 03/28/2023
|
Are These 3 Small Momentum Stocks Setting Up Big Gains?
- MINISO Group Holding Limited (NYSE: MNSO), PDF Solutions Inc. (NASDAQ: PDFS), and Certara Inc. (NASDAQ: CERT) are relatively unknown stocks currently showing strong price momentum.
- 03/22/2023
|
Best Momentum Stocks to Buy for March 15th
- CERT, BWMX and NUE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 15, 2023.
- 03/15/2023
|
New Strong Buy Stocks for March 15th
- TRIN, CERT, WPP, NUE and BHR have been added to the Zacks Rank #1 (Strong Buy) List on March 15, 2023.
- 03/15/2023
|
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
- Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 03/09/2023
|
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates
- Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2023
|
Certara to Participate in the Barclays Global Healthcare Conference
- PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global Healthcare Conference.
- 02/27/2023
|
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
- PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Wednesday, March 1st, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 02/01/2023
|
CERT vs. PBYI: Which Stock Should Value Investors Buy Now?
- CERT vs. PBYI: Which Stock Is the Better Value Option?
- 01/09/2023
|
Why Certara Is A Buy For 2023
- Unlike Schrodinger, Certara posted a profit in the last quarter. Business momentum is accelerating as backlog grows.
- 12/06/2022
|
Why Certara's Shares Rose 37.7% This Week
- The company, which helps other companies in their drug development, reported strong third-quarter numbers.
- 11/11/2022
|
Certara, Inc. (CERT) Q3 Earnings Miss Estimates
- Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/07/2022
|
Certara Inc. (CERT) Q3 2022 Earnings Call Transcript
- Certara Inc. (NASDAQ:CERT ) Q3 2022 Results Conference Call November 7, 2022 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO Andrew Schemick - CFO Conference Call Participants Dave Windley - Jefferies Max Smock - William Blair Luke Sergott - Barclays Joe Vruwink - Baird Wolf Chanoff - Bank of America Lu Li - Credit Suisse Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2022 Earnings Conference Call.
- 11/07/2022
|
Certara to Participate in Upcoming Investor Conferences
- PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:
- 11/02/2022
|
Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022
- PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 after the market close on Monday, November 7th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 10/13/2022
|
Certara to Participate in Upcoming Investor Conferences
- PRINCETON, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences:
- 08/31/2022
|
Here's Why Certara Stock Is Falling Friday
- Certara Inc (NASDAQ: CERT) shares are trading lower by 15.40% to $17.08 Friday morning after the company announced a secondary offering of 7 million shares of common stock. What Else?
- 08/12/2022
|
Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates
- Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2022
|
Certara, Inc.'s (CERT) CEO William Feehery on Q1 2022 Results - Earnings Call Transcript
- Certara, Inc. (NASDAQ:CERT ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants David Deuchler – Investor Relations William Feehery – Chief Executive Officer Andrew Schemick – Chief Financial Officer Conference Call Participants Dave Windley – Jefferies Wolf Chanoff – Bank of America Vikram Purohit – Morgan Stanley Justin Lin – William Blair Jacob Putman – Barclays Vikram Kesavabhotla – Baird Operator Good day, and thank you for standing by. Welcome to the Certara First Quarter 2022 Earnings Conference Call.
- 05/08/2022
|
Certara, Inc. (CERT) Matches Q1 Earnings Estimates
- Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2022
|
Certara to Report First Quarter 2022 Financial Results on May 5th, 2022
- PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 04/20/2022
|
Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?
- Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 03/17/2022
|
Certara, Inc. (CERT) CEO William Feehery on Q4 2021 Results - Earnings Call Transcript
- Certara, Inc. (CERT) CEO William Feehery on Q4 2021 Results - Earnings Call Transcript
- 03/01/2022
|
Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates
- Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2022
|
Certara to Report Fourth Quarter and Full Year 2021 Financial Results on March 1st, 2022
- PRINCETON, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Tuesday, March 1st, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 02/08/2022
|
Certara Looks Positioned For Increased Growth In 2022
- Certara went public in December 2020, raising $337 million in an IPO.
- 02/02/2022
|
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
- Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 01/04/2022
|
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
- The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 01/04/2022
|
Certara (CERT) Stock: Why The Price Dropped Today
- The stock price of Certara Inc (NASDAQ: CERT) fell by over 10% pre-market today. This is why it happened.
- 11/18/2021
|
Certara Inc. (CERT) CEO William Feehery on Q3 2021 Results - Earnings Call Transcript
- Certara Inc. (CERT) CEO William Feehery on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
- PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021 after the market close on Tuesday, November 9th, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 10/19/2021
|
Certara Appoints Drayton T. Virkler as Chief Commercial Officer
- Experienced commercial leader brings 20 years of experience in pharma Experienced commercial leader brings 20 years of experience in pharma
- 10/05/2021
|
Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process
- Cloud-based and validated regulatory software automates and advances quality of patient narratives Cloud-based and validated regulatory software automates and advances quality of patient narratives
- 09/30/2021
|
Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term
- Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term
- 09/29/2021
|
Certara Announces New Clinical Science Group and Adds Senior Scientific Experts
- Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities
- 09/22/2021
|
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
- Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence
- 09/20/2021
|
Certara Announces Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common stock at $31.00 per share. The closing includes 3,000,000 shares sold upon full exercise of the underwriters' option to purchase additional shares of common stock. Certara sold 4,500,000 shares of its common stock, and certain selling stockholders sold 18,500,000 shares of common stock in the offering. The gross proceeds to Certara from the offering were approximately $139.5 million, before deducting the underwriting discount and offering expenses. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara did not receive any proceeds from the sale of shares in the offering by the selling stockholders.
- 09/13/2021
|
CERT Stock: Why It Is Trading Lower Today
- The stock price of Certara Inc (NASDAQ: CERT) dropped over 7% pre-market this morning. This is why it happened.
- 09/09/2021
|
Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount
- Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represents a discount of almost 12% from the last close price of $35.14 on Wednesday.
- 09/09/2021
|
Certara Announces Pricing of Public Offering of Common Stock
- PRINCETON, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its common stock by Certara and certain existing stockholders (“the selling stockholders”) at a price to the public of $31.00 per share. Certara is offering 4.5 million shares of its common stock and certain selling stockholders are offering 15.5 million shares of common stock. Additionally, the selling stockholders have granted the underwriters a 30-day option to purchase up to 3,000,000 additional shares of common stock. The gross proceeds to Certara from the offering will be approximately $139.5 million, before deducting the underwriting discount and estimated offering expenses. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders. The offering is expected to close on or about September 13, 2021, subject to customary closing conditions.
- 09/08/2021
|
Certara Announces Proposed Public Offering of Common Stock
- PRINCETON, N.J., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. Certara is offering 4,500,000 shares of common stock and certain selling stockholders are offering 15,500,000 shares of common stock in the offering. Additionally, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to 3,000,000 additional shares of common stock. Certara intends to use the net proceeds from shares it is selling in the offering for general corporate purposes, including acquisitions. Certara will not receive any proceeds from the sale of shares in the offering by the selling stockholders.
- 09/03/2021
|
Certara to Participate in Upcoming Investor Conferences
- PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:
- 08/31/2021
|
Certara Inc's (CERT) CEO William Feehery on Q2 2021 Results - Earnings Call Transcript
- Certara Inc's (CERT) CEO William Feehery on Q2 2021 Results - Earnings Call Transcript
- 08/07/2021
|
Certara To Buy Compliance Software Provider For $310; Q2 Earnings Beat Expectations, Raises FY21 Guidance
- Certara Inc (NASDAQ: CERT) has agreed to acquire Pinnacle 21 for $310 million in cash and stock. Pinnacle 21's software tools are used to validate compliance to the Clinical Data Interchange Standards Consortium (CDISC) standards, which the FDA requires, Japan's Pharmaceuticals and Medical Devices Agency, and preferred by China's National Medical Products Administration.
- 08/06/2021
|
Certara Reports Second Quarter 2021 Financial Results
- Raises full year 2021 guidance and announces deal to acquire Pinnacle 21 Raises full year 2021 guidance and announces deal to acquire Pinnacle 21
- 08/05/2021
|
Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data
- Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin
- 08/05/2021
|
Mubadala Invests in Global Biosimulation Leader Certara
- PRINCETON, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara. The investment aligns with Mubadala's strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies.
- 07/27/2021
|
Certara's Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19
- Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology
- 07/23/2021
|
Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members
- PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021. The two additional appointments increase the company's board of directors to eleven members.
- 07/15/2021
|
Certara to Report Second Quarter 2021 Financial Results on August 5, 2021
- PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2021 after the market close on Thursday, August 5, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
- 07/14/2021
|
Certara Announces Update of BaseCase Software, the Company's Value Communication Platform
- Major Release to Help Life Science Companies Maximize Go-to-Market Impact Major Release to Help Life Science Companies Maximize Go-to-Market Impact
- 07/08/2021
|
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Biosimulation Software for Evaluating Regulatory Submissions
- The PMDA enters 8th consecutive year of using Certara's biosimulation software The PMDA enters 8th consecutive year of using Certara's biosimulation software
- 06/23/2021
|
Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference
- PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:
- 05/20/2021
|
Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies
- Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges
- 05/13/2021
|
Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call Transcript
- Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance
- PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021.
- 05/06/2021
|
Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier
- First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress
- 05/04/2021
|
Certara: Using Computer Modelling To Aid Biopharma R&D
- Certara is a midsized developer of software for biosimulation. The company has impressive revenues and a strong business model.
- 04/25/2021
|
Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.
- 04/22/2021
|
Certara Announces Closing of Public Offering of Common Stock
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the closing of its underwritten public offering of its common stock at a public offering price of $25.00 per share.
- 03/29/2021
|
Certara Announces Pricing of Public Offering of Common Stock
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the pricing of its public offering of common stock by certain existing stockholders at a price of $25.00 per share.
- 03/24/2021
|
Certara Set to Join Russell 1000® Index
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index.
- 03/11/2021
|
Certara, Inc. (CERT) CEO William Feehery on Q4 2020 Results - Earnings Call Transcript
- Certara, Inc. (CERT) CEO William Feehery on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara, a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ending December 31, 2020.
- 03/04/2021
|
Certara to Present at the Barclays Global Healthcare Conference
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference.
- 02/26/2021
|
The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic Approvals
- PRINCETON, N.J.--(BUSINESS WIRE)--2020 was the 7th consecutive year where 90% of new drug & biologic approvals by the FDA were received by Certara's customers.
- 02/25/2021
|
EQT VII portfolio company Certara closes Initial Public Offering
- STOCKHOLM, Dec. 17, 2020 /PRNewswire/ -- EQT is pleased to announce that on 10 December 2020, the EQT VII portfolio company Certara, Inc. ("Certara"), a global leader in biosimulation based on 2019 revenue, successfully priced its upsized initial public offering of 29,055,000 shares of...
- 12/17/2020
|
IPO Stock Madness Moves to Biotech as AbCellera, Certara Soar
- Hot initial public offerings aren't just for technology companies.
- 12/11/2020
|
Drug Software Firm Certara Expands IPO to Raise $668 Million
- Dec.11 -- Certara Inc., a maker of drug-development software, upsized its initial public offering and priced it above the marketed range to raise $668 million, adding to the red-hot week for U.S. listings. William Feehery, chief executive officer, speaks on "Bloomberg Markets.
- 12/11/2020
|
Certara CEO on strong IPO debut
- CNBC's "Squawk Alley" team discusses Certara's IPO with CEO William Feehery.
- 12/11/2020
|
Certara, AbCellera Lead Flurry of Health-Care IPOs
- Four companies increased the size of their deals.
- 12/11/2020
|
Certara Announces Pricing of Its Upsized Initial Public Offering
- PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share.
- 12/10/2020
|
5 Hot Upcoming IPOs to Watch Heading Into 2021
- The list of upcoming IPOs is starting to perk up. Here's a look at some interesting deals, including a variety of tech operators.
- 12/07/2020
|
